PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 88155208 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 113 |
MARK SECTION | |
MARK | http://uspto.report/TM/88155208/mark.png (stylized and/or with design) |
STANDARD CHARACTERS | NO |
USPTO-GENERATED IMAGE | NO |
OWNER SECTION (current) | |
NAME | Neurocrine Biosciences, Inc. |
MAILING ADDRESS | 12780 El Camino Real |
CITY | San Diego |
STATE | California |
ZIP/POSTAL CODE | 92130 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
XXXX | |
OWNER SECTION (proposed) | |
NAME | Neurocrine Biosciences, Inc. |
MAILING ADDRESS | 12780 El Camino Real |
CITY | San Diego |
STATE | California |
ZIP/POSTAL CODE | 92130 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | B. Brett Heavner |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | docketing@finnegan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | B. Brett Heavner |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | docketing@finnegan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
DOCKET/REFERENCE NUMBER | 14640.1002 |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations for human use for schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and Tourette syndrome, movement disorders, namely, Myoclonus, Huntington's chorea, Levodopa-induced dyskinesia, tardive dyskinesia, dystonia, and tics; Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders; Pharmaceutical preparations for the treatment of tardive dyskinesia |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 3 |
ONGOING EFFORT | product or service research or development |
ALLOWANCE MAIL DATE | 11/12/2019 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 1 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 125 |
TOTAL AMOUNT | 125 |
SIGNATURE SECTION | |
SIGNATURE | /David L. Bradfute/ |
SIGNATORY'S NAME | David L. Bradfute, PhD, JD |
SIGNATORY'S POSITION | Vice President & Head, Intellectual Property |
DATE SIGNED | 05/07/2021 |
SIGNATORY'S PHONE NUMBER | 202-408-4000 (Applicant's attorney) |
SIGNATURE METHOD | Sent to third party for signature |
FILING INFORMATION | |
SUBMIT DATE | Fri May 07 14:16:33 ET 2021 |
TEAS STAMP | USPTO/ESU-XX.XXX.X.X-2021 0507141633708736-88155208 -78063637e9f981f306464952 89aded6f5d268d19b6c99c162 2a693ded5b3940135-CC-1630 0756-20210506142021180529 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |